NCT06068075 is a NA clinical trial of FoundationOne Liquid CDx in Ewing Sarcoma, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT06068075?

NCT06068075 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT06068075?

Interventions in NCT06068075: FoundationOne Liquid CDx.

What condition does NCT06068075 study?

NCT06068075 studies Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma.

Is NCT06068075 still recruiting?

NCT06068075 is currently recruiting now. Last updated 22 January 2026.

Last reviewed 2026-01-22 · How we verify

NCT06068075

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Recruiting now NA Last updated 22 January 2026

What this trial tests

NA trial testing FoundationOne Liquid CDx in Ewing Sarcoma in 340 participants. Currently enrolling.

Timeline

8 May 2018

Primary endpoint
1 January 2027

1 January 2027

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	340
Start date	8 May 2018
Primary completion	1 January 2027
Estimated completion	1 January 2027
Sites	15 locations across United States

Drugs / interventions tested

FoundationOne Liquid CDx

Conditions studied

Ewing Sarcoma — all drugs for Ewing Sarcoma →
Ewing Sarcoma of Bone — all drugs for Ewing Sarcoma of Bone →
Ewing Sarcoma of Soft Tissue — all drugs for Ewing Sarcoma of Soft Tissue →
Peripheral Primitive Neuroectodermal Tumor — all drugs for Peripheral Primitive Neuroectodermal Tumor →

Sponsor

Dana-Farber Cancer Institute

Who can join

Adults 12 Months to 50, any sex, with Ewing Sarcoma or Ewing Sarcoma of Bone. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Unlocking the Potential of ctDNA in Sarcomas: A Review of Recent Advances.
Aiyer S, Kim TH, Collier K, Pollock R, et al · · 2025 · cited 5× · PMID 40149373 · DOI 10.3390/cancers17061040
Early Cancer Detection: What's Going on and What's Next.
Di Carlo E. · · 2026 · PMID 42022539 · DOI 10.1002/mco2.70653

Verify or expand the search:

Other recruiting trials for Ewing Sarcoma

Currently open trials in the same condition.

NCT07297979 — Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) · Phase 1 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
NCT07197554 — A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies · Phase 1 · recruiting
NCT07188532 — Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial · NA · recruiting
NCT07141862 — Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06068075 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06068075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing